Not recruiting
Investigational
Phase 3 Study of ZIGAKIBART (BION-1301) in Adults with IgA Nephropathy
Investigational
- Substances:ZIGAKIBART
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:ZIGAKIBART
- Sponsor:Novartis Pharma AG
Back to ItalyClinical trials in Naples – page 55
1 202 clinical trials in Naples, Italy across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)Naples at a glance
1 202
clinical trials
- Research sites6
Not recruiting
Hepatocellular carcinoma
Not recruitingStudy of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab
Registered drugNo placebo
Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab
Registered drugNo placebo
- Disease:Hepatocellular carcinoma
- Substances:AtezolizumabLenvatinib+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:F. Hoffmann-La Roche AG
Not recruiting
Lung adenocarcinoma
Not recruitingDurvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer
Registered drugNo placebo
Durvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer
Registered drugNo placebo
- Disease:Lung adenocarcinoma
- Substances:CarboplatinCisplatin+5
Countries:Italy
Italy- Participants:65+ years
- Substances:Carboplatin
- Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Not recruiting
Chronic rhinosinusitis with nasal polyps
Not recruitingLong‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study
Investigational
Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study
Investigational
- Disease:Chronic rhinosinusitis with nasal polyps
- Substances:Itepekimab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Itepekimab
- Sponsor:Sanofi-Aventis Recherche & Developpement
Not recruiting
Small cell lung cancer extensive stage
Not recruitingStudy of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients
Registered drugNo placebo
Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients
Registered drugNo placebo
- Disease:Small cell lung cancer extensive stage
- Substances:AtezolizumabCarboplatin+6
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Novartis Pharma AG
Not recruiting
Rheumatoid arthritis
Not recruitingBaricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
Registered drugNo placebo
Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
Registered drugNo placebo
- Disease:Rheumatoid arthritis
- Substances:AdalimumabBaricitinib+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Adalimumab
- Sponsor:Eli Lilly & Co.
Not recruiting
Choroidal neovascularisation
Not recruitingFaricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia
Registered drugNo placebo
Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia
Registered drugNo placebo
- Disease:Choroidal neovascularisation
- Substances:FaricimabRanibizumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Faricimab
- Sponsor:F. Hoffmann-La Roche AG
Not recruiting
Relapsing multiple sclerosis
Not recruitingPhase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis
Registered drug
Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosis
- Substances:FenebrutinibTeriflunomide
Countries:Italy
Italy- Participants:18–64 years
- Substances:Fenebrutinib
- Sponsor:F. Hoffmann-La Roche AG
Not recruiting
Colitis ulcerative+1
Not recruitingA study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis
Investigational
A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis
Investigational
- Disease:Colitis ulcerativeCrohn's disease
- Substances:–
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Sponsor:Sanofi-Aventis Recherche & Developpement
Not recruiting
Cervix carcinoma+1
Not recruitingSacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy
Registered drugNo placebo
Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy
Registered drugNo placebo
- Disease:Cervix carcinomaCervix carcinoma recurrent
- Substances:Codeine PhosphateParacetamol+9
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Codeine Phosphate
- Sponsor:Merck Sharp & Dohme LLC
Not recruiting
Squamous cell carcinoma of head and neck
Not recruitingEfficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Registered drugNo placebo
Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Registered drugNo placebo
- Disease:Squamous cell carcinoma of head and neck
- Substances:PembrolizumabN-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Exelixis Inc.
Not recruiting
Non-small cell lung cancer
Not recruitingEfficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Registered drugNo placebo
Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:CobolimabDocetaxel+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Cobolimab
- Sponsor:Glaxosmithkline Research & Development Limited
Other cities in Italy
The busiest research cities in the country
Clinical research in Naples
What the registry says about research in the country
01 Respiratory Diseases
Research focusing on pulmonary conditions including innovative treatments for idiopathic pulmonary fibrosis and COPD. Studies evaluate new medications like tezepelumab and investigate respiratory syncytial virus vaccines for older adults.
- Idiopathic Pulmonary Fibrosis
- COPD Management
- RSV Prevention
Clinical trials aim to improve lung function and reduce disease progression in patients with chronic respiratory conditions.
02 Oncology Research
Comprehensive studies targeting various cancer types, with emphasis on targeted therapies and immunological approaches. Investigations include treatments for colorectal, gastric, and lung cancers.
- Breast Cancer Prevention
- Gastrointestinal Cancers
- Advanced Solid Tumors
Novel therapeutic combinations and precision medicine approaches are being evaluated for improved patient outcomes.
03 Chronic Diseases
Studies addressing kidney disease, cardiovascular conditions, and neurological disorders. Innovative treatments for Parkinson's disease and end-stage kidney disease are under investigation.
- Kidney Disease Management
- Heart Failure Prevention
- Neurological Disorders
Research focuses on developing safer and more effective treatments for chronic conditions affecting quality of life.